The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Pfizer's revenues will shrink -12.9% and EPS will shrink -9.7%.
The average estimate for revenue is $13.12 billion. On the bottom line, the average EPS estimate is $0.56.
Last quarter, Pfizer logged revenue of $13.50 billion. GAAP reported sales were 9.3% lower than the prior-year quarter's $14.89 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.54. GAAP EPS of $0.38 for Q1 were 58% higher than the prior-year quarter's $0.24 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 80.7%, 140 basis points worse than the prior-year quarter. Operating margin was 33.1%, 120 basis points worse than the prior-year quarter. Net margin was 20.4%, 830 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $51.94 billion. The average EPS estimate is $2.17.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 5,491 members out of 6,080 rating the stock outperform, and 589 members rating it underperform. Among 1,549 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 1,452 give Pfizer a green thumbs-up, and 97 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Pfizer is outperform, with an average price target of $29.99.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Pfizer. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add Pfizer to My Watchlist.